The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
申请公布号
EP3076967(A1)
申请公布日期
2016.10.12
申请号
EP20140867061
申请日期
2014.12.03
申请人
INTRA-CELLULAR THERAPIES, INC.
发明人
VANOVER, KIMBERLY;LI, PENG;MATES, SHARON;DAVIS, ROBERT;WENNOGLE, LAWRENCE P.